-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GlDoAKyE3fxccFHuTX4Lvlow03WTJyBvQFrI6bMNFNHAAIfoOmFwn3wk37as5qid VD/uZEAE/rJo5+6+8I9Qwg== 0000950123-11-015229.txt : 20110217 0000950123-11-015229.hdr.sgml : 20110217 20110217171458 ACCESSION NUMBER: 0000950123-11-015229 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110216 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20110217 DATE AS OF CHANGE: 20110217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: US ONCOLOGY INC CENTRAL INDEX KEY: 0000943061 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 841213501 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26190 FILM NUMBER: 11621705 BUSINESS ADDRESS: STREET 1: 16825 NORTHCHASE DR STREET 2: STE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 BUSINESS PHONE: 2818732674 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN ONCOLOGY RESOURCES INC /DE/ DATE OF NAME CHANGE: 19950327 8-K 1 f58393e8vk.htm FORM 8-K e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 16, 2011
US Oncology, Inc.
(Exact name of registrant as specified in its charter)
         
Delaware   0-26190   84-1213501
(State or other jurisdiction of   (Commission File Number)   (I.R.S. Employer Identification No.)
incorporation)        
     
10101 Woodloch Forest, The Woodlands, Texas   77380
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: (281) 863-1000
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 1.02 Termination of a Material Definitive Agreement.
On February 16, 2011, US Oncology, Inc. (the “Company”) completed its previously disclosed redemption of all of its 9.125% Senior Secured Notes due 2017 (the “9.125% Notes”). The 9.125% Notes were redeemed for a total of approximately $912.5 million, consisting of the principal amount, together with the accrued and unpaid interest thereon and the associated redemption premium of approximately $137.3 million, thereby terminating and discharging all of the Company’s obligations under the 9.125% Notes and the related indenture, dated June 18, 2009, among the Company, the subsidiary guarantors named therein, and Wilmington Trust FSB, as trustee, other than those provisions that survive discharge of the indenture.
On February 17, 2011, the Company completed its previously disclosed redemption of all of its 10.75% Senior Subordinated Notes due 2014 (the “10.75% Notes” and, together with the 9.125% Notes, the “Notes”). The 10.75% Notes were redeemed for a total of approximately $285.0 million, consisting of the principal amount, together with the accrued and unpaid interest thereon and the associated redemption premium of approximately $9.9 million, thereby terminating and discharging all of the Company’s obligations under the 10.75% Notes and the related indenture, dated August 20, 2004, among the Company, the subsidiary guarantors named therein, and Wilmington Trust FSB, as trustee.
The Notes were redeemed pursuant to the previously disclosed Agreement and Plan of Merger, dated as of November 1, 2010, by and among McKesson Corporation (“McKesson”), US Oncology Holdings, Inc. (“Holdings”), Utah Acquisition Corporation, a wholly owned subsidiary of McKesson, and Utah Stockholders’ Agent LLC, as Stockholders’ Agent, pursuant to which Holdings became a direct wholly owned subsidiary of McKesson.

 

 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 17, 2011
         
  US ONCOLOGY, INC.
 		  
  By:   /s/ Willie C. Bogan    
    Willie C. Bogan   
    Vice President and Secretary   
 

 

-----END PRIVACY-ENHANCED MESSAGE-----